Compare drugs
Put two or three records next to each other and contrast their class, mechanism, indications, identifiers, and chemistry. Reads straight from the existing drug records — a reference contrast, never a recommendation.
- atcAngiotensin II receptor blockers (ARBs), plain
- epcAngiotensin 2 Receptor Blocker
- moaAngiotensin 2 Receptor Antagonists
- peDecreased Blood Pressure
- peDecreased Intravascular Volume
- peDecreased Mineralocorticoid Secretion
- peDecreased Renal K+ Excretion
- peIncreased Renal Na+ Excretion
- peRenal Arterial Vasoconstriction
- peRenal Arterial Vasodilation
Lisinopril inhibits angiotensin-converting enzyme (ACE) in human subjects and animals. ACE is a peptidyl dipeptidase that catalyzes the conversion of angiotensin I to the vasoconstrictor substance, angiotensin II.
Angiotensin II [formed from angiotensin I in a reaction catalyzed by angiotensin converting enzyme (ACE, kininase II)] is a potent vasoconstrictor, the primary vasoactive hormone of the renin-angiotensin system, and an important component in the pathophysiology of hypertension. It also stimulates aldosterone secretion by the adrenal cortex.
- Angiotensin-converting Enzyme
- Angiotensin 2 Receptor
- Lisinopril tablet USP is an angiotensin converting enzyme (ACE) inhibitor indicated for: Treatment of hypertension in adults and pediatric patients 6 years of age and older ( 1.1 ) Adjunct therapy for heart failure ( 1.2 ) Treatment of Acute Myocardial Infarction ( 1.3 ) 1.1 Hypertension Lisinopril tablet USP is indicated for the treatment of hypertension in adult patients and pediatric patients 6 years of age and older to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions.I10, I21.9, I50.9
- Losartan potassium tablets are an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.I10
(2S)-1-[(2S)-6-amino-2-[[(1S)-1-carboxy-3-phenylpropyl]amino]hexanoyl]pyrrolidine-2-carboxylic acid
C1C[C@H](N(C1)C(=O)[C@H](CCCCN)N[C@@H](CCC2=CC=CC=C2)C(=O)O)C(=O)O
[2-butyl-5-chloro-3-[[4-[2-(2H-tetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl
- RxCUI
- 29046
- ATC
- C09AA
- UNII
- E7199S1YWR
- RxCUI
- 52175
- ATC
- C09CA
- UNII
- 3ST302B24A